MWNA
ITRM

Marshall Wace North America’s Iterum Therapeutics ITRM Stock Holding History

Marshall Wace North America’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,235
Closed -$202K – 1133
2018
Q2 		$202K Buy
+1,235
New +$223K ﹤0.01% 1272

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
NA
Neuburgh Advisers Los Angeles, California $3.22B AUM 3.74% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return

Marshall Wace North America's ITRM Position: Q3 2018 in Review

Marshall Wace North America sold out of Iterum Therapeutics (ITRM) in Q3 2018, closing a stake of 1,235 shares — an estimated $202K sold.

Marshall Wace North America first reported a position in ITRM in Q2 2018 and held it in 1 quarter. The position peaked at $202K in Q2 2018. 21 funds tracked by Wall St. Rank hold ITRM as of Q3 2018.

  • Marshall Wace North America reported no remaining Iterum Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Marshall Wace North America sold 1,235 Iterum Therapeutics shares in Q3 2018, an estimated $202K.
  • Marshall Wace North America first reported a position in Iterum Therapeutics in Q2 2018 and held it in 1 quarter.
  • Marshall Wace North America's Iterum Therapeutics position peaked at $202K in Q2 2018.
  • 21 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2018.

Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.